I nfection of humans with Plasmodia, the causative agents of malaria, exacts a significant toll on public health, causing pathologies ranging from fever to coma and death (1, 2) . More than 1 million people die annually from Plasmodium infections, and ∼40% of the global population is at risk for exposure (1, 3) . Thus, Plasmodium infection remains an enormous public health problem worldwide, and effective tools to combat infections, including efficacious vaccines, are desperately needed.
Plasmodium species are transmitted through the bite of female Anopheles mosquitoes (4) (5) (6) . Upon inoculation into the naive host, Plasmodium sporozoites enter the blood stream and passively transit to the liver, where they ultimately initiate replication and differentiation in hepatocytes (7, 8) . The liver stage (i.e., preerythrocytic) infection lasts ∼6-8 d in humans and is wholly asymptomatic, whereas the subsequent release of blood stage merozoites from infected hepatocytes underlies clinical malaria. Thus, stopping Plasmodium infection during the asymptomatic liver stage represents an attractive goal of vaccination. By extension, an ideal pre-erythrocytic vaccine to combat human Plasmodium infection would be formulated such that it affords protection against both clinically relevant species of Plasmodium: P. falciparum and P. vivax. However, it is not known whether protective immune responses targeting liver stage infection of multiple Plasmodium species would involve overlapping immune-associated effector molecules or pathways.
Rodent-specific species of Plasmodium, such as P. berghei and P. yoelii, have been widely used to characterize host-parasite interactions, pathogenesis, and protective immunity following inoculation of sporozoites into laboratory mice. Indeed, sporozoite infection of mice exquisitely mimics the early stages of hepatocyte entry and liver stage replication/differentiation that occurs in humans, although with an accelerated time course (7) (8) (9) . For these reasons, P. berghei-or P. yoelii-infected laboratory mice are widely used as models of pre-erythrocytic antiplasmodial vaccination. The most efficacious vaccination strategies targeting liver stage Plasmodium infection use attenuated whole-parasite vaccines, including radiation-attenuated sporozoites (RASs) (10) (11) (12) (13) (14) and genetically attenuated parasites (15) (16) (17) (18) . In rodent models, RAS-and genetically altered parasite-induced protective immunity to liver stage infection requires the induction of CD8 T cell responses (19) (20) (21) . However, the attenuated whole-parasite immunizations also elicit cell-mediated responses that include the participation of CD4 T cells, NK cells, and B cells (21) (22) (23) (24) (25) . Consistent with this multifactorial immune response elicited by whole-parasite immunizations, the immune-associated effector molecules required for protection are complex, and studies of their role in protection are oftentimes conflicting (21, (25) (26) (27) (28) (29) .
Despite decades of research using rodent models of Plasmodium infection to help guide vaccine development and the identification of CD8 T cells as critical mediators of protective immunity against liver stage infection, this work has not yet led to the development of an easily translatable vaccine. Perhaps one reason for this relates to our limited understanding of the precise numerical, phenotypic, and functional requirements for protective memory CD8 T cell responses targeting liver stage Plasmodium infection. In addition, despite the significant biological differences between effector and memory CD8 T cell populations, in terms of transcriptional profile, cell surface phenotype, and functional properties (30) , little consideration has been given to the notion that long-lived, vaccine-induced protection against liver stage Plasmodium infection would be mediated by memory CD8 T cells, not recently stimulated effector CD8 T cells. Indeed, mice multiply immunized with RAS are often challenged 1-2 wk following the last boost, thus evaluating protection by effector rather than true memory CD8 T cells. Similarly, TCR-transgenic (TCR-Tg) CD8 T cells have been used to examine the functional requirements for immunity against liver stage P. yoelii infection, but only during the effector stage of the T cell response (31) (32) (33) . Another point relevant to these previous studies is the assumption that immune-effector pathways are shared between protective CD8 T cells targeting P. berghei or P. yoelii liver stage infection. Thus, the precise characteristics and requirements for memory CD8 T cell-mediated protection against liver stage Plasmodium infection remain poorly characterized. Moreover, whether protective immune-effector pathways overlap for multiple Plasmodium species has never been directly examined.
Using a novel immunization strategy, we recently reported the numerical requirements for immunity mediated solely by memory CD8 T cells against P. berghei liver stage infection (34) . Herein, we use the same immunization approach, in which the sole immune cells mediating protection are bona fide endogenous polyclonal populations of memory CD8 T cells, to dissect the phenotypic and functional requirements for memory CD8 T cellmediated protection against liver stage P. berghei and P. yoelii infection. We generated P. berghei-or P. yoelii-specific memory CD8 T cell responses in wild-type (WT) and BALB/c mice lacking expression of key immune-effector molecules to test the hypothesis that multiple CD8 T cell effector mechanisms are required for memory CD8 T cell-mediated protection of mice challenged with Plasmodium sporozoites. Our results reveal that IFN-g and TNF-a contribute to memory CD8 T cell-mediated protection against P. berghei and P. yoelii liver stage infection, but perforin only plays a role in resolving P. yoelii infection. Thus, key immune-effector molecules differentially regulate memory CD8 T cell-mediated immunity for two species of rodent Plasmodium.
Materials and Methods

Mice and immunizations
Specific pathogen-free WT BALB/c mice were purchased from the National Cancer Institute. Specific pathogen-free IFN-g 2/2 (GKO), FIGURE 1. Similar kinetics and magnitude of memory CD8 T cell responses following DC-CS 252-260 -prime, LM-CS 252-260 -boost immunization of WT and mutant BALB/c mice. A, Experimental design. Parasitespecific memory CD8 T cell responses were generated in WT and mutant BALB/c mice as described in Materials and Methods. The magnitude, kinetics, and phenotype of CS 252-260 -specific memory CD8 T responses in the blood, liver, or spleen were characterized more than 60 d post immunization. B, Representative H2-K perforin 2/2 (PKO), and gld BALB/c mice were maintained in our own breeding colonies. TRAIL 2/2 (TRAIL-KO) BALB/c mice were provided by Dr. Thomas Griffith, University of Iowa. Mice were immunized as previously described (34) . Briefly, mice were primed via tail vein injection of 1 3 10 6 splenic DCs coated with peptide corresponding to circumsporozoite (CS) [252] [253] [254] [255] [256] [257] [258] [259] [260] or CS 280-288 for P. berghei or P. yoelii, respectively. Seven days later, mice were boosted with 2 3 10 7 CFU Listeria monocytogenes-CS (LM-CS) [252] [253] [254] [255] [256] [257] [258] [259] [260] or LM-CS 280-288 . All animal studies were approved by the University of Iowa Animal Care and Use Committee.
Mosquitoes and parasites
Female Anopheles stephensi (Liston) mosquitoes strain STE2 (MR4-128, MR4, ATCC) infected with P. berghei ANKA clone 234 were obtained from Iowa State University. Female A. stephensi mosquitoes infected with P. yoelii yoelii clone 17XNL were provided by the insectary at New York University (New York, NY). Infectious P. berghei and P. yoelii sporozoites were hand dissected from mosquito salivary glands, evaluated for viability using propidium iodide staining, counted, and inoculated into mice via tail vein injection, as previously described (34) .
Enumeration of Ag-specific CD8 T cells 
Functional avidity and TCR Vb-chain use
For functional avidity analyses, splenocytes were harvested from immunized mice and stimulated ex vivo in the presence of 10-fold dilutions of peptide corresponding to CS 252-260 . After 5.5 h, cells were stained for intracellular TNF-a, as described above. Data were normalized to the frequency of CS 252-260 -specific CD8 T cells detected using the highest titration of peptide (1 mM 
TLR agonist administration
Naive WT BALB/c mice were infected with P. berghei or P. yoelii sporozoites, as indicated. At various times, mice were administered 100 mg CpG i.p. (ODN1826, IDT, Coralville, IA), 1 mg LPS i.v., or 200 mg (poly)I:C i.v. (both from Sigma-Aldrich, St. Louis, MO). Serum cytokine analyses were performed following the administration of TLR agonists using BioPlex Assay (Bio-Rad, Hercules, CA).
In vivo cytokine neutralization
One-half milligram of anti-TNF-a (clone XT-22), 0.5 mg anti-IFN-g (clone XMG1.2), or 0.5 mg normal rat IgG2a was administered by i.p. injection 1 d before and 1 d following sporozoite challenge, or as indicated.
Evaluation of parasitemia
Thin blood smears were performed on naive and immunized mice 10 d following sporozoite challenge. Parasitized RBCs were identified by Giemsa stain. Protection is defined as the absence of blood stage parasitemia following examination $15 high-powered (3100) fields.
Statistics
Statistical significance was determined by the Student t or x 2 test where indicated.
Results
P. berghei-specific memory CD8 T cells are generated and persist in WT and mutant BALB/c mice following DC-prime, L. monocytogenes-boost immunization
We recently reported a novel immunization strategy in BALB/c mice that elicits a population of memory CD8 T cells that affords life-long protection against multiple P. berghei sporozoite challenges. By design, memory CD8 T cells are the only cell-type capable of providing sterile protection against liver stage infection in this system. Thus, this model permits the direct study of the immunological mechanisms that contribute to memory CD8 T cell-mediated protection against liver stage Plasmodium infection. Therefore, to test our central hypothesis, we generated Plasmodium-specific memory CD8 T cell populations in BALB/c WT, GKO, PKO, TRAIL-KO, and gld (lacking functional Fas ligand [FasL]) mice, as previously described (34) . Briefly, animals were immunized via tail vein with 1 3 10 6 WT splenic dendritic cells (DCs) coated with peptides corresponding to the immunodominant H-2K d -restricted CD8 T cell determinant derived from the CS protein of P. berghei (DC-CS 252-260 ) or P. yoelii (DC-CS 280-288 ). Seven days later, mice were boosted with 2 3 10 7 CFU of an attenuated recombinant strain of L. monocytogenes expressing the same minimal determinant as a secreted fusion protein (LM-CS 252-260 or LM-CS 280-288 ). We previously showed that attenuated L. monocytogenes is cleared on day 2 in DC-primed WT mice (35) and that immune GKO and PKO mice clear virulent L. monocytogenes with similar kinetics as WT mice (36, 37) . Sixty to 100 d postimmunization, when numerically and phenotypically stable memory CD8 T cell populations had been established, CS 252-260 -immune WT and mutant BALB/c mice were challenged with 1000 P. berghei sporozoites, a stringent challenge dose approximately five times the infectious dose (ID 50 ) for naive BALB/c mice (data not shown).
It is well known that the absence of IFN-g and/or perforin influences the magnitude of Ag-specific primary memory CD8 T cell responses in BALB/c mice (38) . For this reason, we first determined whether the absence of IFN-g, perforin, TRAIL, or functional FasL influenced the kinetics, magnitude, or distribution of Plasmodium-specific memory CD8 T cells following DC-prime, L. monocytogenes-boost immunization of WT and mutant BALB/c mice (Fig. 1A) . Using MHC class I tetramer reagents (Fig. 1B) , we found that prime-boost immunization elicited CS 252-260 -specific memory CD8 T cell responses in mutant mice that were as large or larger than responses in WT BALB/c mice in the spleen, blood, and liver ( Fig. 1C, 1E ). In the case of mice lacking IFN-g or perforin, the numbers of memory CD8 T cells were ∼25-40% higher in each tissue compartment analyzed compared with WT BALB/c mice ( Fig. 1C, 1E ). These data also reveal that the relationship between circulating and tissue-resident CS 252-260 -specific CD8 T cell numbers are maintained among WT and mutant BALB/c mice, independent of the absence of key immune-effector molecules (Fig. 1E ). The numerical relationships between memory CD8 T cell responses among WT and mutant mice were also preserved T cells recovered from the spleens of the WT, GKO, and PKO mice. The concentration of CS 252-260 peptide required to elicit the 1/2 maximal response was determined as described in Materials and Methods. Data represent the mean 6 SD for three mice/group. F, Polyfunctionality of WT and mutant (IFN-gcompetent) CS 252-260 -specific memory CD8 T cells. PBMCs from the indicated mouse strains were stimulated ex vivo in the presence of CS 252-260 peptides. The proportion of single-, double-, or triple-positive cytokine-producing cells was determined by Boolean gating using FlowJo software. Data represent mean 6 SD for seven to 10 individual mice/strain. when we examined the ability of circulating (Fig. 1D ) and tissueresident (data not shown) CS 252-260 -specific memory cells to produce TNF-a following ex vivo stimulation with peptide. In addition to these data examining P. berghei (CS 252-260 )-specific responses, we observed similar memory CD8 T cell responses in WT and mutant BALB/c mice immunized against P. yoelii using the CS 280-288 CD8 T cell determinant (data not shown). Collectively, these results showed that the magnitude of the immunization-induced memory CD8 T cell response in mutant BALB/c mice is as large or larger than in WT mice, independent of the lack of the relevant immune-effector molecules.
We next determined whether the phenotype, TCR repertoire, or functional avidity differed among WT and mutant memory CD8 T cell responses following DC-prime, L. monocytogenes-boost immunization. When we examined CS 252-260 -specific memory CD8 T cells .80 d following DC-prime, L. monocytogenes-boost immunization, we found no striking differences in cell surface expression of CD127, CD27, CD43 glyco (1B11), CD44, CD62L, or killer cell lectin-like receptor subfamily G member 1 on CS 252-260 -specific memory CD8 T cells recovered from the spleen, blood, or liver of WT and mutant mice ( Fig. 2A, 2B ). Furthermore, we also observed no differences in TCR Vb-chain repertoire or functional avidity ( Fig. 2C-E ; for simplicity, data not shown for TRAIL-KO and gld). Recent work identified correlations between memory CD8 T cell polyfunctionality and their protective capacity in the context of Plasmodium sporozoite challenge (39) . When we evaluated the ability of memory CD8 T cells to coproduce IFN-g, TNFa, and IL-2, we found no marked differences among WT and mutant (IFN-g-competent) memory CD8 T cells (Fig. 2F) . Collectively, the data in Figs. 1 and 2 argue that any potential differences in memory CD8 T cell-mediated protection among WT and mutant BALB/c mice following sporozoite challenge would be due to the lack of the relevant immune-effector molecule, not a consequence of reduced parasite-specific memory CD8 T cell numbers, altered distribution, or cell surface phenotype.
Memory CD8 T cell-mediated protection against P. berghei liver stage infection is associated with expression of IFN-g but not expression of perforin, TRAIL, or functional FasL
We recently reported that ∼95% long-term protection against P. berghei sporozoite challenge could be achieved in WT BALB/c mice if the frequency of immunization-induced CS 252-260 -specific memory CD8 T cells exceeds 1% of all PBMCs (34) . In that scenario, protection was defined as the prevention of blood stage parasitemia following challenge with 1000 P. berghei sporozoites. Using this same approach, we first evaluated the ability of memory CD8 T cells in WT, GKO, and PKO BALB/c mice to mediate resistance to P. berghei sporozoite challenge. For these studies, cohorts of WT and mutant mice were DC primed and L. monocytogenes boosted, as described above. More than 60 d following boost, the frequency of circulating CS 252-260 -specific CD8 T cells was determined in individual mice, which were ranked by immune status to reveal potential numerical effects on protection (Fig. 3A) . Three to 4 d later, groups of mice were challenged with 1000 P. berghei sporozoites. In line with our previous work, .93% (29/31) of immunized WT mice resisted the sporozoite challenge and remained protected from the development of blood stage parasitemia. In the same experiments, we found that 100% (18/18) of PKO mice exhibiting .1% CS 252-260 -specific PBLs resisted the sporozoite challenge (x 2 = 1.21; p = 0.271 for WT versus PKO). In contrast, we found that only 45% of GKO mice resisted P. berghei sporozoite challenge ( Fig. 3A; x 2 = 11.62; p = 0.00065 for WT versus GKO). Importantly, only one of 24 GKO animals displayed circulating T cell numbers below the 1% threshold required for 95% protection in WT BALB/c mice. Thus, the enhanced susceptibility of GKO mice is not due to reduced numbers of CS 252-260 -specific memory CD8 T cells. These data clearly demonstrate an important, but nonessential, role for IFN-g in memory CD8 T cell-mediated protection against P. berghei liver stage infection. Moreover, these data show that the absence of direct perforin-mediated killing of infected hepatocytes by memory CD8 T cells does not influence protective immunity following P. berghei sporozoite challenge.
Inflammatory or microbial insults to the liver can result in hepatocyte upregulation of the TRAIL receptor DR5 (40) . Furthermore, in models of influenza-infected mice, engagement of DR5 by TRAIL expressed on CD8 T cells can result in the enhanced elimination of virus-infected DR5 + target cells (41), similar to the cell death pathway triggered following engagement of Fas by FasL (42) . For these reasons, we next evaluated protection in TRAIL-deficient and gld BALB/c mice (lacking functional FasL). We found that immune mice deficient in TRAIL displayed no defect in resistance to sporozoite challenge, with 100% (16/16) of animals resisting sporozoite challenge ( Fig. 3B; x 2 = 0.952; p = 0.329 for WT versus TRAIL-KO). Furthermore, when we examined protection in gld BALB/c mice, we found similar resistance between gld and WT mice, with .1% circulating CS 252-260 -specific memory CD8 T cells ( Fig.  3C; x 2 =1.56; p = 0.211). Thus, in a setting in which memory CD8 T cells are the only cell type capable of mediating protection, our data identify IFN-g as an important component of the pathways of protection against liver stage P. berghei infection. Collectively, these data suggest that memory CD8 T cellmediated protection against liver stage P. berghei infection does not strictly depend on direct memory CD8 T cell killing of infected hepatocytes through extrinsic cell death pathways involving perforin, TRAIL, or FasL.
TNF-a contributes to memory CD8 T cell-mediated protective immunity against liver stage P. berghei infection
The observation that IFN-g is a critical component of resistance raises the possibility that additional inflammatory cytokines may be involved in memory CD8 T cell-mediated protection against P. berghei liver stage infection. A significant proportion of memory CD8 T cells coexpress IFN-g and TNF-a upon Ag re-encounter (43), and TNFR1 is rapidly induced on hepatocytes following liver injury or insult (44) . It was also shown that TNF-a, in conjunction with IL-6, can inhibit the in vitro differentiation of pre-erythrocytic forms of Plasmodia (45-47). Thus, we hypothesized that TNF-a may also play an important role in memory CD8 T cell-mediated protection against P. berghei sporozoite challenge. Because the tnfa gene lies within the MHC locus, tnfa -/-mice are not available on the BALB/c background. Therefore, we performed in vivo neutralization of this cytokine in immune BALB/c mice via two i.p. injections of the anti-TNF-a mAb clone XT-22 (Fig. 4A) . Strikingly, we found that in DC-prime, L. monocytogenes-boost-immunized WT BALB/c mice with .1% circulating CS 252-260 -specific memory CD8 T cells, the in vivo neutralization of TNF-a sharply reduced memory CD8 T cell-mediated protection from 100% to ,60% ( Fig.  4B; x 2 = 8.36; p = 0.004). These results clearly identify an in vivo role for TNF-a in protection mediated by memory CD8 T cells. As a composite, our data identify two inflammatory cytokines (IFN-g and TNF-a) as important regulators of protective immunity against liver stage P. berghei infection mediated by immunization-induced memory CD8 T cells. Collectively, these data highlight the importance of indirect antiparasitic activities of IFN-g and TNF-a on P. berghei-infected hepatocytes and de-emphasize the contribution of direct target cell killing through extrinsic cell death pathways involving perforin, TRAIL, and FasL.
Pathways of memory CD8 T cell-mediated protection are nonoverlapping for P. yoelii and P. berghei liver stage infection
We next extended our studies to determine the relative contributions of these same key immune-effector molecules following P. yoelii sporozoite challenge of DC-prime, L. monocytogenesboost BALB/c mice. When we immunized cohorts of WT, GKO, and PKO mice against the CS 280-288 determinant derived from P. yoelii, we found that .82% of WT mice resisted a challenge of 100 P. yoelii sporozoites (Fig. 5A) , a physiological challenge dose that is approximately eight times the ID 50 for naive BALB/c mice (data not shown). Similar to our results following P. berghei challenge, these experiments also revealed a profound defect in the ability of immunized GKO mice to resist P. yoelii sporozoite challenge, with only half of mice remaining free of blood stage infection ( Fig. 5A; x 2 = 5.31; p = 0.021 for WT versus GKO). However, and in contrast to P. berghei, a substantial fraction (,55%) of PKO mice were also unable to resist P. yoelii sporozoite challenge ( Fig. 5A; x 2 = 7.94; p = 0.005 for WT versus PKO). These results indicate that IFN-g and perforin play an important role in memory CD8 T cell-mediated protection against P. yoelii liver stage infection. Moreover, these data show that the pathways of memory CD8 T cell-mediated protection differ for two rodent species of Plasmodium. Of note, although the numerical threshold for memory CD8 T cell-mediated resistance of WT BALB/c mice to P. yoelii sporozoite challenge has not been formally investigated, these data hint that the threshold may be higher than that previously reported for P. berghei (34) . Nevertheless, on average, greater numbers of CS 280-288 -specific memory CD8 T cells were detected in GKO and PKO mice evaluated in these experiments, ruling out that enhanced susceptibility of mice lacking IFN-g or perforin is due to reduced numbers of memory CD8 T cells that develop following DC-prime, L. monocytogenesboost immunization. Importantly, we also investigated whether the enhanced susceptibility of immunized PKO mice to P. yoelii challenge could be related to impaired cytokine expression in cells lacking perforin. However, an examination of the mean fluorescence intensity (MFI) of TNF-a staining in WT versus PKO CS 280-288 -specific memory CD8 T cells following ex vivo stimulation revealed that PKO cells express ∼40% more TNF-a on a per cell basis compared with WT cells (TNF-a MFI = 5730 6 840 and 8972 6 322 in WT and PKO cells, respectively; p = 0.0173). In contrast, the per cell expression of IFN-g was not significantly different between PKO and WT CS 280-288 -specific memory CD8 T cells (IFN-g MFI = 1810 6 400 and 2298 6 550 in WT and PKO cells, respectively; p = 0.151). Thus, impaired cytokine expression by PKO CS 280-288 -specific memory CD8 T cells is unlikely to explain the enhanced susceptibility of PKO mice relative to WT mice.
Based on the striking susceptibility phenotype of immunized PKO mice following P. yoelii sporozoite challenge, we further evaluated the potential contribution of other pathways involved in target cell elimination through direct killing by memory CD8 T cells, including FasL and TRAIL. However, when we evaluated cohorts of immunized WT, gld, and TRAIL-deficient BALB/c mice, there was no evidence of enhanced susceptibility in the mice lacking functional FasL or TRAIL expression compared with WT BALB/c mice ( Fig. 5B; x 2 = 0.004, p = 0.949 for WT versus gld; x 2 = 0, p = 1.0 for WT versus TRAIL-KO). Together, these data suggest that IFN-g and perforin, but not FasL or TRAIL, play important roles in the protection mediated by memory CD8 T cells against liver stage P. yoelii infection.
Having identified TNF-a as a novel component of memory CD8 T cell-mediated protection against P. berghei liver stage infection,
The Journal of Immunologywe also evaluated the role of this cytokine in the setting of P. yoelii sporozoite challenge of immunized mice. WT BALB/c mice were immunized against the CS 280-288 determinant, T cell responses were assayed in the peripheral blood, and mice were subsequently challenged with 100 P. yoelii sporozoites. The mAb XT-22 or rat IgG was administered 1 d before and 1 d after challenge (Fig. 6A) . When we assayed for blood stage parasitemia 10 d after sporozoite challenge, we found that protection was reduced from 70% in rat IgG-treated mice to 10% following in vivo neutralization of TNF-a ( Fig. 6B; x 2 = 7.50; p = 0.006). Thus, as we observed for the P. berghei model, TNF-a plays an important role in memory CD8 T cell-mediated protection against liver stage P. yoelii infection.
Systemic inflammation triggered 24 h after sporozoite challenge prevents P. berghei but not P. yoelii liver stage development and subsequent blood stage infection It was reported that direct recognition of P. yoelii-infected hepatocytes by CS 280-288 -specific TCR-Tg effector CD8 T cells is required for protective immunity (48) . However, our data raise the possibility that for P. yoelii and P. berghei, recognition of other noninfected CS Ag-bearing cells (i.e., Kupffer cells, DCs, and parasite-traversed hepatocytes) by memory CD8 T cells could also initiate or potentiate the release of inflammatory cytokines. Therefore, such cytokines could collaterally influence Plasmodium survival or differentiation within infected cells at a distance from the APC-memory T cell conjugate. Thus, given a clear role for IFN-g and TNF-a proinflammatory cytokines in halting liver stage P. berghei and P. yoelii infection of immunized mice, we reasoned that systemic TLR agonist-induced inflammation might be sufficient to protect mice following challenge with either species of parasite.
Previous work determined that TLR9 agonist (CpG)-induced generalized inflammation triggered prior to P. yoelii sporozoite challenge was sufficient to protect mice from the development of blood stage infection (49) . However, we wished to ensure that we were evaluating effects on liver stage development and not hepatocyte entry or initiation of infection. Thus, we administered TLR agonists 24 h postchallenge, giving the parasites time to establish liver infection (Fig. 7A) . This time frame is particularly reasonable, given that the liver stage developmental program for rodent Plasmodium strains is generally completed by 48-60 h (9). Strikingly, for groups of mice infected with 1000 P. berghei sporozoites and subsequently treated with TLR9, TLR4, or TLR3 agonists (CpG, LPS, or poly(I:C), respectively), we observed that all treatments blocked liver stage differentiation and protected 100% of mice from the development of blood stage infection (Fig.  7B) . In contrast, none of the TLR agonists proved sufficient to block liver stage differentiation following infection with 100 P. yoelii sporozoites when administered 24 h postchallenge (Fig.  7B) . To determine whether IFN-g and/or TNF-a contributed to the results observed with P. berghei-infected CpG-treated mice, we neutralized these cytokines in parallel experiments. We found that we could partially reverse the protective effect of CpG treatment on P. berghei liver stage development following neutralization of TNF-a or IFN-g (Fig. 7C) , demonstrating that the protective effect of the TLR9 agonist is partially mediated by these two cytokines. Previous reports suggested that P. yoelii replicates faster in the rodent liver compared with P. berghei, based on the kinetics of parasite rRNA accumulation (50) . Therefore, we attempted to determine whether a window of susceptibility to inflammation exists for P. yoelii. To do this, we administered CpG 1 d prior, during, or at regular intervals after sporozoite challenge. In line with previous studies (49), we found that pretreatment of mice with CpG partially prevented the development of blood stage P. yoelii parasitemia (Fig. 7D) . We also determined that P. yoelii is only partially susceptible to the effects of CpG following sporozoite challenge and only if CpG is administered by 12 h postchallenge (Fig. 7D) . Collectively, these data show that although there is partial overlap, there are significant and inherent differences between two rodent species of Plasmodia with respect to the immune-effector molecules that act to prevent or block liver stage differentiation.
Discussion
In this study, we demonstrated that there are overlapping immuneeffector pathways, such as those involving IFN-g or TNF-a, and nonoverlapping pathways, such as perforin-associated direct killing, used by CS-specific memory CD8 T cells to prevent P. berghei and P. yoelii liver stage infection. We also demonstrated that the generalized inflammation is sufficient to halt liver stage P. berghei, but not P. yoelii, survival or differentiation. Collectively, our data showed that certain key immune-effector molecules differentially impact CS-specific memory CD8 T cell-mediated protective immunity to liver stage Plasmodium infection and that the pathways that limit or prevent liver stage infection are, in part, Plasmodium species specific. Whether the immune-effector pathways are similar for protective memory CD8 T cells targeting non-CS Ags remains to be determined. However, our data clearly showed that resistance to the pre-erythrocytic cycle of Plasmodia infections mediated by bona fide CS-specific memory CD8 T cells is multifactorial, with no single immune-effector molecule required for sterile protection.
Although a role for IFN-g in preventing liver stage Plasmodia infection has long been described in the context of whole-parasite immunization models, our results are the first to show that IFN-g is central to protection mediated by bona fide CS-specific memory CD8 T cells. Indeed, for several studies using attenuated wholeparasite immunization, the contribution of IFN-g has been controversial (21, (25) (26) (27) (28) . Although the reasons for these disparate results are not clear, they are likely related to unequal numbers, phenotype, or distribution of parasite-specific CD8 T cells that arise following RAS immunization of WT, GKO, or IFN-gR 2/2 mice; the participation of additional arms of the adaptive immune response following multiple whole-parasite immunizations, including CD4
T cells and Ab-secreting B cells; or the timing of the sporozoite challenge: RAS-immune mice and recipients of WT or GKO TCRTg T cells are generally challenged very early following the last booster immunization (1-2 wk). For RAS models, this early challenge is performed because RAS-induced immunity often wanes (12, 14, 51, 52) . Thus, most previous work commonly examined protection during the effector phase of the CD8 T cell response, in systems wherein parasite-specific CD4 T cells and Abs also contribute to protection. Recent work in our laboratory has ruled out any protective contribution of CD4 T cells and Abs in DC-prime, L. monocytogenes-boost-immunized mice (53) . Indeed, the experiments described in our study directly examine protection mediated by late-memory (.60 d postimmunization) CS-specific CD8 T cells and clearly demonstrate a critical role for IFN-g in protection against Plasmodium liver stage infection. Given the exceedingly high numerical requirements for sterilizing immunity following sporozoite challenge (34), we did not find it feasible to evaluate sterilizing antisporozoite immunity following adoptive transfer of WT and mutant CS-specific memory CD8 T cells. Although it may be possible to examine reductions in parasite rRNA burden in such adoptive-transfer experiments, this requires challenging mice with supraphysiological doses of sporozoites (∼10,000), a scenario that we wished to avoid. Thus, we have been unable to address a memory CD8 T cell-intrinsic role for IFN-g. In contrast, the use of sterilizing immunity as a read-out for protection also has limitations, because the elimination of all but a single infected hepatocyte can still result in blood stage parasitemia. Indeed, we cannot rule out that vaccinated GKO mice that succumbed to blood stage infection following P. berghei sporozoite challenge (Fig. 3A) may well have eliminated 99% of infected hepatocytes. Nevertheless, our studies convincingly demonstrate the contribution of IFN-g in the most stringent of settings (the requisite targeting of 100% of infected hepatocytes) in which CS-specific memory CD8 T cells are the only adaptive immune cell type capable of responding to the early liver stage of the parasite infection. How IFN-g contributes to protection in vivo is not definitively established, but several studies have implicated IFN-g-induced hepatocyte upregulation of inducible NO synthase (iNOS) as a critical component of this cytokine's protective effect. Indeed, the administration of inhibitors of iNOS to sporozoite-challenged RAS-vaccinated mice or hepatocyte cultures has suggested an important role for hepatocyte-derived NO in limiting parasite survival and/or development within infected cells (19, 28, 54) . We attempted to evaluate the contribution of iNOS to our CSspecific memory CD8 T cell-mediated protective model, but we were unable to find any effect following in vivo administration of the iNOS inhibitors N6-(1-iminoethyl)-L-lysine, dihydrochloride or aminoguanidine to DC-primed, L. monocytogenes-boosted WT BALB/c mice (data not shown). However, we did find a very modest effect following in vivo administration of another inhibitor of iNOS s-methylisothiourea (data not shown), suggesting that in our model the IFN-g/TNF-a-iNOS axis contributes to protection. It was also suggested that CD8 T cell-derived IFN-g functions through a positive feedback loop involving the induction of IL-12 from liver macrophages or DCs, which subsequently triggers the release of additional IFN-g from liverresident NK cells (23, 55) . When we examined the potential contribution of this pathway in our immunization model, we found no difference in the ability of DC-prime, L. monocytogenes-boostimmunized IL-12p40 2/2 BALB/c mice to resist sporozoite challenge when compared with WT mice (data not shown). Lastly, in vitro administration of IFN-g was shown to induce the upregulation of hepatocyte MHC class I. Thus, in our model it is possible that IFN-g induces MHC class I expression on infected target cells, which may enhance recognition by memory CD8 T cells as they mediate protection thorough direct cytotoxicity or through the elaboration of antiparasitic cytokines. Indeed, whether IL-12, iNOS, or the upregulation of hepatocyte MHC class I is central to the protective pathways mediated by IFN-g-competent CS-specific memory CD8 T cells remains to be determined. The novel observation of a protective role for TNF-a in the context of memory CD8 T cell-mediated protective immunity is also of interest. Similar to IFN-g, this proinflammatory cytokine was shown to participate in the induction of iNOS when administered in combination with IL-6 to cultured hepatocytes (45) (46) (47) . Interestingly, when we monitored serum cytokine changes following sporozoite challenge of naive and immunized WT BALB/c mice, we found that only IL-6 and IFN-g (among 15 other cytokines and chemokines) were significantly upregulated (data not shown). Thus, in the context of P. berghei sporozoite challenge, where the parasite is sensitive to nonspecific generalized inflammation (Fig. 4) , TNF-a may act in concert with IL-6 (and possibly IFN-g) to limit parasite survival or block differentiation within hepatocytes. Whether IL-6 and TNF-a or IFN-g and TNFa act synergistically in our model of CS-specific memory CD8 T cell-mediated protection is under investigation.
The notion that memory CD8 T cells afford protection against P. berghei and P. yoelii via at least one nonoverlapping effector pathway was surprising. Our data suggest that for P. berghei, it may be sufficient for CS-specific memory CD8 T cells to initiate or potentiate an inflammatory cascade that culminates in the developmental inhibition or killing of parasites within host hepatocytes via TNF-a and/or IFN-g. Thus, although direct killing of infected hepatocytes by CS-specific memory CD8 T cells may contribute to protection against P. berghei liver infection, our data show that this mode is nonessential, because removal of the classical extrinsic cell death pathways mediated by cytotoxic CD8 T cells (i.e., perforin, FasL, and TRAIL) does not influence protection. In contrast, significantly reduced protection in PKO mice following P. yoelii sporozoite challenge suggests greater emphasis on pathways involving direct killing of infected cells in the context of P. yoelii infection, independent of the FasL-and TRAIL-mediated pathways. This surprising observation suggests the possibility that for other species of Plasmodia, including the two clinically relevant human species P. falciparum and P. vivax, the pathways of CD8 T cellmediated protective immunity may also differ.
Although efforts thus far have met with limited success, the development of an efficacious pre-erythrocytic vaccine remains an important goal for combating human Plasmodium infection. Our work identifies critical similarities and differences between the pathways that CS-specific memory CD8 T cells use to protect against liver stage infection for two species of rodent Plasmodia. Our work also implicates TNF-a as an additional critical in vivo component of protective antisporozoite immunity. Whether similar discordance in protective memory CD8 T cell effector molecules FIGURE 7 . Generalized inflammation protects against P. berghei, but not P. yoelii, liver stage infection. Experimental overview (A) and tabulated results (B) of P. berghei and P. yoelii sporozoite challenge studies conducted with the TLR agonists CpG, LPS, and poly(I:C). Data in B are pooled results from three independent experiments. Numbers indicate the percentage protected (no. protected/no. challenged). C, Neutralization of TNF-a or IFN-g abrogates CpG-induced protection against P. berghei sporozoite challenge. Neutralizing Abs were administered to mice at the time of sporozoite challenge. Data are the results from a single experiment. D, P. yoelii is less susceptible to generalized inflammation induced by administration of CpG to naive WT BALB/c mice. CpG was administered at the indicated time surrounding P. yoelii sporozoite challenge. Data are pooled results from two independent experiments. and pathways exists for the two clinically relevant species of human Plasmodia, P. falciparum and P. vivax, remains to be determined. However, our data highlight that key differences may exist and that such information should be considered in the rational design of vaccines targeting liver stage Plasmodium infection of humans.
